Latest Developments in the Treatment of Anal Cancer

Video

This video reviews the standard of care for locally advanced anal carcinoma, examines new trials studying novel agents and immunotherapy in the advanced setting, and highlights the need for HPV vaccination for preventing the disease.

In this video, Cathy Eng, MD, of the University of Texas MD Anderson Cancer Center, reviews the standard of care for locally advanced anal carcinoma, including options for chemotherapy, which is used concurrently with radiation therapy, and surgery for patients with bulky tumors and for those who aren’t cured with chemoradiotherapy.

In the metastatic setting, investigational trials are studying novel agents and immunotherapy-a recently published phase II trial found that 24% of treatment-refractory patients responded to nivolumab. These ongoing studies could change the way patients with advanced disease are treated.

Eng also highlights the need for human papillomavirus (HPV) vaccination for the prevention of this disease as well as other HPV-related cancers.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.